Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/20110402http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/20110402http://www.w3.org/2000/01/rdf-schema#comment"

Objective

To assess the long-term effect of prepubertal high-dose GH treatment on growth in children with idiopathic short stature (ISS).

Design and methods

Forty children with no signs of puberty, age at start 4-8 years (girls) or 4-10 years (boys), height SDS <-2.0 SDS, and birth length >-2.0 SDS, were randomly allocated to receive GH at a dose of 2 mg/m(2) per day (equivalent to 75 microg/kg per day at start and 64 microg/kg per day at stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of treatment with low or intermediate doses of GH separated by two washout periods of 3 months) or no treatment. In 28 cases, adult height (AH) was assessed at a mean (S.D.) age of 20.4 (2.3) years.

Results

GH-treated children (mean treatment period on high-dose GH 2.3 years (range 1.2-5.0 years)) showed an increased mean height SDS at discontinuation of the treatment compared with the controls (-1.3 (0.8) SDS versus -2.6 (0.8) SDS respectively). However, bone maturation was significantly accelerated in the GH-treated group compared with the controls (1.6 (0.4) versus 1.0 (0.2) years per year, respectively), and pubertal onset tended to advance. After an untreated interval of 3-12 years, AH was -2.1 (0.7) and -1.9 (0.6) in the GH-treated and control groups respectively. Age was a positive predictor of adult height gain.

Conclusion

High-dose GH treatment restricted to the prepubertal period in young ISS children augments height gain during treatment, but accelerates bone maturation, resulting in a similar adult height compared with the untreated controls."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.org/dc/terms/identifier"doi:10.1530/eje-09-0880"xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"Oostdijk W."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"Wit J.M."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"Delemarre-van de Waal H.A."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"de Muinck Keizer-Schrama S.M."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"Kamp G.A."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"Odink R.J."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/author"van Gool S.A."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/date"2010"xsd:gYear
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/name"Eur J Endocrinol"xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/pages"653-660"xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/title"High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height."xsd:string
http://purl.uniprot.org/citations/20110402http://purl.uniprot.org/core/volume"162"xsd:string
http://purl.uniprot.org/citations/20110402http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/20110402
http://purl.uniprot.org/citations/20110402http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/20110402
http://purl.uniprot.org/uniprot/P01241#attribution-2BD56587A063B5526B1025DAD0DE5621http://purl.uniprot.org/core/sourcehttp://purl.uniprot.org/citations/20110402